Monday, November 16, 2026
Form 4 reports shares bought or sold by company insiders such as officers, directors or large holders.
Thursday, November 12, 2026
Azenta Faces Inquiry From Law Office Over Possible Securities Claims
A legal practice is examining whether Azenta may face claims tied to securities matters. The announcement gave no added details about the scope or basis of the review.
Needham lifts its Azenta valuation estimate to $57
An analyst firm raised its target for where Azenta shares could trade, now set at $57. This is a routine update to a prior estimate.
Wednesday, November 11, 2026
Jefferies keeps Buy rating on Azenta, lifts price target to $52
Jefferies repeated its Buy rating on Azenta and raised its price target to $52. The change reflects the analyst's updated view of the stock.
Tuesday, November 10, 2026
Azenta Releases Q4 and Full-Year 2026 Results
Azenta published its financial figures for the final three months of 2026 and for the entire year. The release details the company's performance over both periods.
Form 8-K tells shareholders about important events such as deals, leadership changes or results.
Azenta posts Q4 adjusted profit of $0.28 per share, topping $0.11 consensus
Azenta's fourth-quarter adjusted earnings came in at $0.28 per share, ahead of the $0.11 analysts expected. Revenue of $167.088 million also exceeded the $160.133 million consensus.
Azenta forecasts FY2027 sales of $648M to $660M
Azenta issued its outlook for fiscal 2027, projecting revenue between $648 million and $660 million. That range sits above the $639.051 million analyst estimate.
Friday, October 30, 2026
Azenta Announces Strategic Investments in GENEWIZ Capabilities
Azenta said it is making strategic investments aimed at advancing the capabilities of its GENEWIZ business. The announcement gives no financial terms or timeline.
Azenta acquires SynPlexity and signs exclusive DNA synthesis license with Elegen
Azenta said it is buying SynPlexity, a maker of gene libraries, and has secured an exclusive license from Elegen covering DNA synthesis technology. Financial terms were not disclosed.
Monday, September 14, 2026
Needham Reiterates Buy Rating on Azenta, Keeps $37 Price Target
Needham repeated its buy rating on Azenta and left its $37 price target unchanged. The analyst firm is maintaining its prior stance on the stock.
Friday, September 4, 2026
Thelema settles $35M obligation to Azenta early
Thelema has fully repaid a $35 million loan from Azenta ahead of schedule. The funds were tied to Azenta's divestment of B Medical Systems.
Monday, August 24, 2026
Azenta CEO John Marotta resigns; shares trade lower
Azenta announced that John Marotta has stepped down from his roles as President and CEO. The company's stock moved lower following the news.
Azenta names Martin Madaus interim president and CEO, keeps Q4 revenue outlook
Azenta appointed Martin Madaus as interim president and chief executive officer. The company also repeated its fourth-quarter revenue outlook.
Frequently asked questions
What is the latest news on AZTA?
Nov 16, 2026: Azenta, Inc. filed an insider trading report (Form 4) (SEC) · Nov 12, 2026: Azenta Faces Inquiry From Law Office Over Possible Securities Claims (Fiscal.ai) · Nov 12, 2026: Needham lifts its Azenta valuation estimate to $57 (Fiscal.ai)
What has AZTA filed with the SEC recently?
Nov 16, 2026: Azenta, Inc. filed an insider trading report (Form 4) · Nov 10, 2026: Azenta, Inc. filed a report on a major company event (Form 8-K)
Get AZTA news as it happens
Every headline, SEC filing and analyst action for AZTA on your live chart, with important news marked and alerts when it matters.
Try SEPT Free